Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms

Abstract excerpt

The pediatric lysosomal storage disorder mucopolysaccharidosis type II is caused by mutations in IDS, resulting in accumulation of heparan and dermatan sulfate, causing severe neurodegeneration, skeletal disease, and cardiorespiratory disease. Most patients manifest with cognitive symptoms, which cannot be treated with enzyme replacement therapy, as native IDS does not cross the blood-brain barrier. We tested a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cellular transport and secretion
• Share to Lysosomal Storage Disorders Research
• Share to Neurogenetic and Muscular Disorders Research